TG
TGTX
—
Nasdaq
Pharmaceuticals
Tg Therapeutics, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
7,4B USD
P/E
13,7x
EV / Rev
10,3x
Div yield
—
Op margin
20,0 %
ROE
76,7 %
Net margin
72,6 %
Debt / equity
1,28
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$53,53
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
TG THERAPEUTICS, INC. is classified under Healthcare / Pharmaceuticals and appears profitable on the latest normalized snapshot.
Business. TG THERAPEUTICS, INC. (TGTX) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a participant in the pharmaceuticals market.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · rules-based
Sell-side consensus
BUY8 analysts
7 buy0 hold1 sell
Avg 12m price target67,83
Analyst recommendations
8 analysts · consensus BuyBuy7
Hold0
Sell1
12-month price target
67,83
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation→
13,7x
P/E
Analysts→
Buy
8 analysts · indicative
Ownership
—
not yet wired
Profitability→
76,7 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to TGTX. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
TG THERAPEUTICS, INC. (TGTX) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a participant in the pharmaceuticals market.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDTG THERAPEUTICS, INC. (TGTX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the latest snapshot: total assets 1,528,837,000 USD, total equity 583,131,000, short-term debt 0, long-term debt 745,140,000. Net cash position is approximately -230,710,000 USD. Self-calculated market cap is 6,136,789,579 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 204,918,000, gross profit 0, operating income 34,795,000, net income 19,777,000. Return on equity ~76.7%. Return on assets ~29.2%. Operating-cash-flow to net-income ratio is -0.06. Risk profile from automated assessment: liquidity risk medium, dilution risk high. Flags: Diluted share count is moderately above the basic share count.; Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] allocator_boost: allocator_boost (allocator) on TGTX — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-02; rank=14; ev=8.645847; company_id=507ebed4-defc-4b9a-920e-fc34d9cf7f45; term_contributions={'event_proximity': 2.456192, 'gradability': 2.0, 'staleness': 4.189655, 'credibility_interest': 0.0}; days_since_analysis=65; pending_promises=0; reason=Allocator coverage boost rank #14 EV=8.645847 for TGTX (hot+stale; days_since=65); calendar_week={'next_event_date': '2026-08-03', 'days_until': 1, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-08-02:TGTX). Additional context: allocator_boost: watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-02; rank=14; ev=8.645847; company_id=507ebed4-defc-4b9a-920e-fc34d9cf7f45; term_contributions={'event_proximity': 2.456192, 'gradability': 2.0, 'staleness': 4.189655, 'credibility_interest': 0.0}; days_since_analysis=65; pending_promises=0; reason=Allocator coverage boost rank #14 EV=8.645847 for TGTX (hot+stale; days_since=65); calendar_week={'next_event_date': '2026-08-03', 'days_until': 1, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator.
Key takeaways
- Observed GAAP P/E is about 13.72x.
- Return on equity is about 76.7%.
- Debt to equity is about 1.28x.
- [TRIGGER] allocator_boost: allocator_boost (allocator) on TGTX — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-02; rank=14; ev=8.645847; company_id=507ebed4-defc-4b9a-920e-fc34d9cf7f45; term_contributions={'event_proximity': 2.456192, 'gradability': 2.0, 'staleness': 4.189655, 'credibility_interest': 0.0}; days_since_analysis=65; pending_promises=0; reason=Allocator coverage boost rank #14 EV=8.645847 for TGTX (hot+stale; days_since=65); calendar_week={'next_event_date': '2026-08-03', 'days_until': 1, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-08-02:TGTX)
- Companyfacts coverage was partial; recent filing facts backfilled property_and_equipment, goodwill.
- 0001001316 2026-01-01 2026-03-31 xbrli:shares 0001001316 2026-05-01 thunderdome:item iso4217:USD 0001001316 2026-03-31 0001001316 2025-12-31 iso4217:USD xbrli:shares 0001001316 us-gaap:ProductMember 2026-01-01 2026-03-31 0001001316 us-gaap:ProductMember 2025-01-01 2025-03-31 0001001316 us-gaap:LicenseMember 2026-01-01 2026-03-31 0001001316 us-gaap:LicenseMember 2025-01-01 2025-03-31 0001001316 2025-01-01 2025-03-31 0001001316 us-gaap:CommonStockMember 2024-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001001316 us-gaap:TreasuryStockCommonMember 2024-12-31 0001001316 us-gaap:RetainedEarningsMember 2024-12-31 0001001316 2024-12-31 0001001316 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001001316 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001001316 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001001316 us-gaap:CommonStockMember 2025-03-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001001316 us-gaap:TreasuryStockCommonMember 2025-03-31 0001001316 us-gaap:RetainedEarningsMember 2025-03-31 0001001316 2025-03-31 0001001316 us-gaap:CommonStockMember 2025-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001001316 us-gaap:TreasuryStockCommonMember 2025-12-31 0001001316 us-gaap:RetainedEarningsMember 2025-12-31 0001001316 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001001316 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001001316 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001001316 us-gaap:CommonStockMember 2026-03-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001001316 us-gaap:TreasuryStockCommonMember 2026-03-31 0001001316 us-gaap:RetainedEarningsMember 2026-03-31 0001001316 tgtx:CommercializationAgreementWithNeuraxpharmMember 2026-01-01 2026-03-31 0001001316 tgtx:UnvestedRestrictedStockMember 2026-01-01 2026-03-31 0001001316 tgtx:UnvestedRestrictedStockMember 2025-01-01 2025-03-31 0001001316 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001001316 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001001316 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001001316 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001001316 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-03-31 0001001316 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-03-31 0001001316 tgtx:LicenseRevenueMember 2026-01-01 2026-03-31 0001001316 tgtx:LicenseRevenueMember 2025-01-01 2025-03-31 0001001316 us-gaap:ProductMember country:US 2026-01-01 2026-03-31 0001001316 tgtx:NeuraxpharmMember us-gaap:ProductMember 2026-01-01 2026-03-31 0001001316 us-gaap:ProductMember 2026-03-31 0001001316 us-gaap:ProductMember 2025-03-31 xbrli:pure 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerOneMember 2026-01-01 2026-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerOneMember 2025-01-01 2025-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerTwoMember 2026-01-01 2026-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerTwoMember 2025-01-01 2025-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerThreeMember 2026-01-01 2026-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerThreeMember 2025-01-01 2025-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerFourMember 2026-01-01 2026-03-31 0001001316 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerFourMember 2025-01-01 2025-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerOneMember 2026-01-01 2026-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerOneMember 2025-01-01 2025-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerTwoMember 2026-01-01 2026-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerTwoMember 2025-01-01 2025-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerThreeMember 2026-01-01 2026-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerThreeMember 2025-01-01 2025-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerFourMember 2026-01-01 2026-03-31 0001001316 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember tgtx:CustomerFourMember 2025-01-01 2025-03-31 0001001316 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-31 0001001316 us-gaap:USGovernmentAgenciesDebtSecuritiesMember tgtx:LongTermInvestmentsMember 2026-03-31 0001001316 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0001001316 us-gaap:USGovernmentAgenciesDebtSecuritiesMember tgtx:LongTermInvestmentsMember 2025-12-31 0001001316 tgtx:BriumviUblituximabMember 2026-03-31 0001001316 tgtx:BriumviUblituximabMember 2026-01-01 2026-03-31 0001001316 tgtx:PrecisionLicenseAgreementMember 2024-01-07 2024-01-07 0001001316 tgtx:PrecisionLicenseAgreementMember 2024-01-07 0001001316 srt:MaximumMember tgtx:PrecisionBiosciencesIncMember 2024-01-07 2024-01-07 0001001316 tgtx:PrecisionBiosciencesIncMember 2024-01-07 0001001316 tgtx:PrecisionBiosciencesIncMember tgtx:ReverseStockSplitMember 2024-02-01 2024-02-28 0001001316 tgtx:PrecisionBiosciencesIncMember 2025-01-07 2025-01-07 0001001316 tgtx:PrecisionBiosciencesIncMember 2025-01-07 utr:D 0001001316 tgtx:PrecisionLicenseAgreementMember 2026-02-23 2026-02-23 0001001316 tgtx:PrecisionLicenseAgreementMember 2026-02-23 0001001316 srt:MaximumMember tgtx:PrecisionBiosciencesIncMember 2026-02-23 2026-02-23 0001001316 tgtx:PrecisionBiosciencesIncMember 2026-02-23 2026-02-23 utr:Y 0001001316 tgtx:PrecisionBiosciencesIncMember 2025-12-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember 2010-03-01 2010-03-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember 2010-03-31 0001001316 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001001316 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001001316 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001001316 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001001316 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001001316 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001001316 srt:MaximumMember 2024-08-02 0001001316 2024-08-02 2025-12-31 0001001316 srt:MaximumMember tgtx:The2025ShareRepurchaseProgramMember 2025-09-01 0001001316 srt:MaximumMember tgtx:The2025ShareRepurchaseProgramMember 2026-03-31 0001001316 tgtx:The2025ShareRepurchaseProgramMember 2025-09-02 2026-03-31 0001001316 us-gaap:RestrictedStockMember tgtx:The2012IncentivePlanMember 2026-03-31 0001001316 tgtx:The2012IncentivePlanMember 2026-03-31 0001001316 tgtx:The2012IncentivePlanMember 2025-12-31 0001001316 tgtx:The2022IncentivePlanMember 2025-06-11 0001001316 tgtx:The2022IncentivePlanMember 2025-06-12 0001001316 us-gaap:RestrictedStockMember tgtx:The2022IncentivePlanMember 2026-03-31 0001001316 tgtx:The2022IncentivePlanMember 2026-03-31 0001001316 us-gaap:RestrictedStockMember 2025-12-31 0001001316 us-gaap:RestrictedStockMember 2024-12-31 0001001316 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001001316 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0001001316 us-gaap:RestrictedStockMember 2026-03-31 0001001316 us-gaap:RestrictedStockMember 2025-03-31 0001001316 us-gaap:RestrictedStockMember tgtx:StockbasedCompensationExpenseCapitalizedIntoInventoryMember 2026-01-01 2026-03-31 0001001316 us-gaap:RestrictedStockMember tgtx:StockbasedCompensationExpenseCapitalizedIntoInventoryMember 2025-01-01 2025-03-31 0001001316 tgtx:MilestoneBasedRestrictedStockMember 2026-03-31 0001001316 tgtx:MilestoneBasedRestrictedStockMember 2026-01-01 2026-03-31 0001001316 tgtx:MarketbasedRestrictedStockMember 2026-03-31 0001001316 tgtx:MarketbasedRestrictedStockMember 2026-01-01 2026-03-31 0001001316 tgtx:StockTrackingUnitsStusMember 2026-03-31 0001001316 tgtx:StockTrackingUnitsStusMember 2026-01-01 2026-03-31 0001001316 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001001316 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001001316 us-gaap:EmployeeStockOptionMember 2026-03-31 0001001316 tgtx:WarrantsToPurchaseCommonStockAmendedLoanAgreementMember 2026-03-31 0001001316 tgtx:WarrantsToPurchaseCommonStockFirstAmendmentLoanAgreementMember 2026-03-31 0001001316 tgtx:WarrantsToPurchaseCommonStockFirstAmendmentMember 2026-03-31 0001001316 tgtx:InitialTermLoanMember 2024-08-02 0001001316 tgtx:InitialTermLoanMember us-gaap:FederalFundsEffectiveSwapRateMember 2024-08-02 2024-08-02 0001001316 tgtx:InitialTermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-08-02 2024-08-02 0001001316 tgtx:The2026TermLoanMember 2026-03-18 0001001316 tgtx:The2026TermLoanMember us-gaap:FederalFundsEffectiveSwapRateMember 2026-03-18 2026-03-18 0001001316 tgtx:The2026TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2026-03-18 2026-03-18 0001001316 tgtx:The2026TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2026-03-18 0001001316 tgtx:The2026TermLoanMember us-gaap:BaseRateMember 2026-03-18 0001001316 tgtx:The2026TermLoanMember 2026-03-18 2026-03-18 0001001316 tgtx:InitialTermLoanMember 2026-01-01 2026-03-31 0001001316 tgtx:TheFirstAmendmentTermLoanMember 2026-03-31 0001001316 tgtx:TheFirstAmendmentTermLoanMember 2025-12-31 0001001316 tgtx:TheFirstAmendmentTermLoanMember 2026-01-01 2026-03-31 0001001316 tgtx:TheFirstAmendmentTermLoanMember 2025-01-01 2025-12-31 0001001316 tgtx:The2026TermLoanMember 2026-03-31 0001001316 tgtx:The2026TermLoanMember 2026-01-01 2026-03-31 utr:sqft 0001001316 tgtx:OfficeSpaceInNewYorkCityLeasedByFbioMember 2014-10-31 0001001316 tgtx:OfficeSpaceInNewYorkCityLeasedByFbioMember 2026-01-01 2026-03-31 0001001316 tgtx:GansevoortLeaseMember 2026-03-31 0001001316 tgtx:GansevoortLeaseMember 2026-03-01 2026-03-31 0001001316 tgtx:TheNorthCarolinaLeaseMember 2021-10-31 0001001316 tgtx:TheNorthCarolinaLeaseMember 2021-10-01 2021-10-31 0001001316 tgtx:TheNorthCarolinaLeaseMember srt:MaximumMember 2026-01-01 2026-03-31 0001001316 srt:MinimumMember 2026-03-31 0001001316 srt:MaximumMember 2026-03-31 0001001316 tgtx:OfficeSpaceInNewYorkCityLeasedByFbioMember 2019-02-28 0001001316 tgtx:TheNorthCarolinaLeaseMember 2021-12-31 0001001316 tgtx:LFBLicenseAgreementMember 2012-01-01 2026-03-31 0001001316 tgtx:LFBLicenseAgreementMember 2026-03-31 0001001316 us-gaap:LicenseAgreementTermsMember tgtx:LFBLicenseAgreementMember 2012-01-31 0001001316 tgtx:LFBLicenseAgreementMember 2026-01-01 2026-03-31 0001001316 tgtx:CommercializationAgreementWithNeuraxpharmMember 2023-07-28 2023-07-28 0001001316 us-gaap:ProductMember tgtx:BriumviUblituximabMember 2023-07-28 0001001316 tgtx:CommercializationAgreementWithNeuraxpharmMember 2023-07-28 0001001316 tgtx:CommercializationAgreementWithNeuraxpharmMember 2026-03-31 0001001316 tgtx:PrecisionLicenseAgreementMember 2026-02-01 2026-02-28 0001001316 tgtx:PrecisionLicenseAgreementMember 2026-02-28 0001001316 srt:MaximumMember tgtx:PrecisionLicenseAgreementMember 2026-02-01 2026-02-28 0001001316 tgtx:StrategicPlatformLicenseAgreementWithMaxcyteIncMember 2025-02-10 2025-02-10 0001001316 tgtx:StrategicPlatformLicenseAgreementWithMaxcyteIncMember 2025-02-10 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
Bull / Bear case
Generated · model-assistedBULL CASE · 3
Tg Therapeutics achieved FY2025 revenue of $616.3 million, demonstrating significant top-line growth compared to prior fiscal periods.
Analysts maintain a buy recommendation with a mean price target of $44.33, implying 15.6% upside from current levels.
Operating income grew to $123.3 million in FY2025, reflecting strong operational leverage and profitability expansion.
BEAR CASE · 5
Free cash flow remained negative at -$25.0 million in FY2025, indicating ongoing cash burn despite profitability.
The company faces high dilution risk, which could negatively impact shareholder value and equity ownership percentages.
Long-term debt increased to $245.6 million in FY2025, raising leverage concerns despite low credit risk flags.
Cash conversion ratio of -0.06 places the company in the bottom quartile of its pharmaceutical peer cohort.
Debt-to-equity ratio of 1.28 ranks in the bottom quartile compared to the pharmaceutical industry median of 0.16.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $204.9M; Operating income $34.8M.
Revenue$204.9M
Operating income$34.8M
Net income$19.8M
Free cash flow-$17.9M
EPS—
Operating cash flow-$17.9M
Financials
Income statement
Revenue$204.9M
Gross profit—
Operating income$34.8M
Net income$19.8M
Margins
Gross margin—
Operating margin17.0%
Net margin9.7%
FCF margin-8.8%
Balance sheet
Total assets$1.53B
Total liabilities$945.7M
Total equity$583.1M
Cash & equivalents$442.2M
Long-term debt$745.1M
Cash flow
Operating cash flow-$17.9M
CapEx$51.0k
Free cash flow-$17.9M
SBC$19.9M
P&L flow · revenue → net income
Highlights
- ▍Revenue $204.9M
- ▍Operating income $34.8M
- ▍Net margin 9.7%
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Revenue $423.7M; Operating income $72.8M.
Revenue$423.7M
Operating income$72.8M
Net income$424.1M
Free cash flow-$44.6M
EPS—
Operating cash flow-$44.4M
Financials
Income statement
Revenue$423.7M
Gross profit—
Operating income$72.8M
Net income$424.1M
Margins
Gross margin—
Operating margin17.2%
Net margin100.1%
FCF margin-10.5%
Balance sheet
Total assets$1.03B
Total liabilities$417.8M
Total equity$607.2M
Cash & equivalents$74.1M
Long-term debt$245.3M
Cash flow
Operating cash flow-$44.4M
CapEx$147.0k
Free cash flow-$44.6M
SBC$49.0M
P&L flow · revenue → net income
Highlights
- ▍Revenue $423.7M
- ▍Operating income $72.8M
- ▍Net margin 100.1%
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Revenue $262.0M; Operating income $43.5M.
Revenue$262.0M
Operating income$43.5M
Net income$33.2M
Free cash flow-$21.3M
EPS—
Operating cash flow-$21.3M
Financials
Income statement
Revenue$262.0M
Gross profit—
Operating income$43.5M
Net income$33.2M
Margins
Gross margin—
Operating margin16.6%
Net margin12.7%
FCF margin-8.1%
Balance sheet
Total assets$702.6M
Total liabilities$426.2M
Total equity$276.4M
Cash & equivalents$129.1M
Long-term debt$245.0M
Cash flow
Operating cash flow-$21.3M
CapEx$67.0k
Free cash flow-$21.3M
SBC$31.3M
P&L flow · revenue → net income
Highlights
- ▍Revenue $262.0M
- ▍Operating income $43.5M
- ▍Net margin 12.7%
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $616.3M; Operating income $123.3M.
Revenue$616.3M
Operating income$123.3M
Net income$447.2M
Free cash flow-$25.0M
EPS—
Operating cash flow-$24.8M
Financials
Income statement
Revenue$616.3M
Gross profit—
Operating income$123.3M
Net income$447.2M
Margins
Gross margin—
Operating margin20.0%
Net margin72.6%
FCF margin-4.1%
Balance sheet
Total assets$1.06B
Total liabilities$415.2M
Total equity$648.0M
Cash & equivalents$79.1M
Long-term debt$245.6M
Cash flow
Operating cash flow-$24.8M
CapEx$214.0k
Free cash flow-$25.0M
SBC$64.7M
P&L flow · revenue → net income
Highlights
- ▍Revenue $616.3M
- ▍Operating income $123.3M
- ▍Net margin 72.6%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $329.0M; Operating income $41.9M.
Revenue$329.0M
Operating income$41.9M
Net income$23.4M
Free cash flow-$40.6M
EPS—
Operating cash flow-$40.5M
Financials
Income statement
Revenue$329.0M
Gross profit—
Operating income$41.9M
Net income$23.4M
Margins
Gross margin—
Operating margin12.7%
Net margin7.1%
FCF margin-12.3%
Balance sheet
Total assets$577.7M
Total liabilities$355.3M
Total equity$222.4M
Cash & equivalents$179.9M
Long-term debt$244.4M
Cash flow
Operating cash flow-$40.5M
CapEx$45.0k
Free cash flow-$40.6M
SBC$42.5M
P&L flow · revenue → net income
Highlights
- ▍Revenue $329.0M
- ▍Operating income $41.9M
- ▍Net margin 7.1%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $329.0M; Operating income $41.9M.
Revenue$329.0M
Operating income$41.9M
Net income$23.4M
Free cash flow-$40.6M
EPS—
Operating cash flow-$40.5M
Financials
Income statement
Revenue$329.0M
Gross profit—
Operating income$41.9M
Net income$23.4M
Margins
Gross margin—
Operating margin12.7%
Net margin7.1%
FCF margin-12.3%
Balance sheet
Total assets$577.7M
Total liabilities$355.3M
Total equity$222.4M
Cash & equivalents$179.9M
Long-term debt$244.4M
Cash flow
Operating cash flow-$40.5M
CapEx$45.0k
Free cash flow-$40.6M
SBC$42.5M
P&L flow · revenue → net income
Highlights
- ▍Revenue $329.0M
- ▍Operating income $41.9M
- ▍Net margin 7.1%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $233.7M; Operating income $20.6M.
Revenue$233.7M
Operating income$20.6M
Net income$12.7M
Free cash flow-$31.4M
EPS—
Operating cash flow-$31.4M
Financials
Income statement
Revenue$233.7M
Gross profit—
Operating income$20.6M
Net income$12.7M
Margins
Gross margin—
Operating margin8.8%
Net margin5.4%
FCF margin-13.4%
Balance sheet
Total assets$329.6M
Total liabilities$169.1M
Total equity$160.5M
Cash & equivalents$92.9M
Long-term debt$100.1M
Cash flow
Operating cash flow-$31.4M
CapEx$0.00
Free cash flow-$31.4M
SBC$37.9M
P&L flow · revenue → net income
Highlights
- ▍Revenue $233.7M
- ▍Operating income $20.6M
- ▍Net margin 5.4%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $233.7M; Operating income $20.6M.
Revenue$233.7M
Operating income$20.6M
Net income$12.7M
Free cash flow-$31.4M
EPS—
Operating cash flow-$31.4M
Financials
Income statement
Revenue$233.7M
Gross profit—
Operating income$20.6M
Net income$12.7M
Margins
Gross margin—
Operating margin8.8%
Net margin5.4%
FCF margin-13.4%
Balance sheet
Total assets$329.6M
Total liabilities$169.1M
Total equity$160.5M
Cash & equivalents$92.9M
Long-term debt$100.1M
Cash flow
Operating cash flow-$31.4M
CapEx$0.00
Free cash flow-$31.4M
SBC$37.9M
P&L flow · revenue → net income
Highlights
- ▍Revenue $233.7M
- ▍Operating income $20.6M
- ▍Net margin 5.4%
Valuation FY
Market price
$45,95
Market cap
$6.14B
Enterprise valueⓘ
$6.37B
P/Eⓘ
13.7x
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
10.3x
EV / Op incomeⓘ
51.6x
EV / OCFⓘ
—
P / Bⓘ
10.5x
P / Tangible bookⓘ
10.5x
Tangible book
$582.3M
Net cashⓘ
-$230.7M
Current ratioⓘ
5.8
Debt / equityⓘ
1.3
ROAⓘ
29.2%
ROEⓘ
76.7%
Cash conversionⓘ
-6.0%
CapEx / revenueⓘ
0.0%
SBC / revenueⓘ
10.5%
Dilution ratioⓘ
4.5%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs TGTX · multiples and returns
JN
JNJ—
Johnson & Johnson
$254,43
622,1B USDP/E
23,5x
+9,8 vs self
Div yield
2,0 %
— vs self
ROE
33,0 %
-43,7 vs self
LL
LLY—
ELI LILLY AND COMPANY
$1 124,04
1,01T USDP/E
52,0x
+38,3 vs self
Div yield
0,5 %
— vs self
ROE
66,2 %
-10,5 vs self
MR
MRK—
MERCK & CO., INC.
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
PF
PFE—
Pfizer Inc
$25,05
143,6B USDP/E
18,2x
+4,5 vs self
Div yield
6,9 %
— vs self
ROE
8,6 %
-68,1 vs self
AB
ABBV—
Abbvie Inc
$245,10
434,8B USDP/E
110,6x
+96,9 vs self
Div yield
2,5 %
— vs self
ROE
-63,5 %
-140,2 vs self
AZ
AZN—
AZN.L
$157,59
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BM
BMY—
Bristol-myers Squibb Co
$65,60
134,3B USDP/E
17,7x
+4,0 vs self
Div yield
4,1 %
— vs self
ROE
31,6 %
-45,1 vs self
GS
GSK—
Gsk Plc-spon Adr
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 43 %
EPS
Consensus EPS
1,38
Predicted surprise
+0,08
Beat probability
43 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,04 · as of 2026-08-02 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,38 |
| Revenue | —no estimate | —no estimate | 942,4M USD |
| Operating income | —no estimate | —no estimate | 265,3M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy1
Buy6
Hold0
Sell1
Strong sell0
12-month price target$67,83 · Median $74,00
Low $20,00High $86,00
Operating income · consensus265,3M USD
EPS surprise
+100,5 %
reported vs consensus · beat
Revenue surprise
−34,6 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$20,00
Mean$67,83
Median$74,00
High$86,00
Spot$45,95
+47.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskHigh
Liquidity riskMedium
Filing-based flags
- Diluted share count is moderately above the basic share count.
- Net cash is negative after subtracting total debt.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin20,0 %Above P75
Net Margin72,6 %Best in class
ROE76,7 %Best in class
Capex / Rev0,0 %Above P75
D/E1,28Bottom quartile
Cash Conv-0,06Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 41 625 sh5 grants5 insiders
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
- Director · Stock Tracking Unit → Common StockAcquired 8 325grant · 2026-06-11
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- TG THERAPEUTICS, INC. company facts · 2026-08-02
- TG THERAPEUTICS, INC. 10-Q 2026-05-06 · 2026-08-02
- TG THERAPEUTICS, INC. 10-K 2026-02-27 · 2026-08-02
- TG THERAPEUTICS, INC. 10-Q 2025-11-05 · 2026-08-02
- TG THERAPEUTICS, INC. 10-Q 2025-08-08 · 2026-08-02
- allocator_boost (allocator) on TGTX · 2026-08-02
- TG Therapeutics Inc Market data — analyst estimates · 2026-08-02
- TG Therapeutics Inc Market data — ESG · 2026-08-02
- TG THERAPEUTICS, INC. HA canonical relationships · 2026-08-02
Ownership & reference
Insider activity
Net selling0 buys · 2 sellsnet -$835K5 insiders · last 365d
- Director · Common StockOther 13 197 · 2026-01-29
- Director · Common StockOther 30 000 · 2026-01-28
- Director, CEO · Common StockOther 622 000 · 2026-01-08
- CFO · Common StockOther 90 000 · 2026-01-08
- Director · Common StockSold 5 000 @ $32,57$163K · 2025-11-24
- Director, CEO · Common StockOther 803 717 · 2025-11-05
- Director, CEO · Common StockOther 3 865 126 · 2025-11-05
- Director · Common StockSold 20 852 @ $32,24$672K · 2025-09-11
Short positioning
30.7Mshares short+1.7% vs prior
15.45days to cover
30.2%short of daily vol
2fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
TGTXCanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskHigh
Liquidity riskMedium
Diluted share count is moderately above the basic share count.
Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 16.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 194.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 69.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 87.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 191.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 84.1%Derived (calculated)
- Net margin (FY 2025-12-31): 72.6%Derived (calculated)
- Return on equity (FY 2025-12-31): 69.0%Derived (calculated)
- Return on assets (FY 2025-12-31): 42.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.10xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.64xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 375.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -56.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 161.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 1,837.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 1,746.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 1,811.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 38.9%Derived (calculated)
- Pre-tax income (annual): USD 107.39MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 3SEC XBRL filing
- Long-term debt (annual): USD 245.65MSEC XBRL filing
- Current liabilities (annual): USD 153.76MSEC XBRL filing
- Net income (annual): USD 447.2MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-08-03EVENTQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-11 00:00 UTCINSIDER5 insider transactions — 2026-06 5 derivative
2026-06-11INSIDERHoberman Kenneth acquired 8.3k sh Stock Tracking Unit — Director
2026-06-11INSIDERHUME DANIEL acquired 8.3k sh Stock Tracking Unit — Director
2026-06-11INSIDERLonial Sagar acquired 8.3k sh Stock Tracking Unit — Director
2026-06-11INSIDERCharney Laurence N acquired 8.3k sh Stock Tracking Unit — Director
2026-06-11INSIDEREchelard Yann acquired 8.3k sh Stock Tracking Unit — Director
2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 204.9M · Net USD 19.8M
2026-01-29 00:00 UTCINSIDER4 insider transactions — 2026-01
2026-01-29INSIDERCharney Laurence N transacted 13.2k sh — Director
2026-01-28INSIDERCharney Laurence N transacted 30.0k sh — Director
2026-01-08INSIDERWEISS MICHAEL S transacted 622.0k sh — Director, CEO
2026-01-08INSIDERPower Sean A transacted 90.0k sh — CFO
2025-12-31EARNINGSQuarterly results — Q3 2025
2025-12-31EARNINGSAnnual results — FY 2025 Revenue USD 616.3M · Net USD 447.2M
2025-11-24 00:00 UTCINSIDER3 insider transactions — 2025-11 · net sell $163k
2025-11-24INSIDEREchelard Yann sold 5.0k sh — Director ~$163k
2025-11-05INSIDERWEISS MICHAEL S transacted 803.7k sh — Director, CEO
2025-11-05INSIDERWEISS MICHAEL S transacted 3.87M sh — Director, CEO
Showing the 40 most recent of 50 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage